Biotechnology
Filter News
Found 21,804 articles
-
AmpliPhi Biosciences to Hold 2017 Third Quarter and Business Update Conference Call on November 14
11/9/2017
AmpliPhi Biosciences announced that management will hold a business update conference call on Tuesday, November 14, 2017 beginning at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).
-
The cuts were expected to save the company $500M.
-
Five Prime stock took a beating after it unintentionally released Phase Ia/Ib clinical trial of its CSF-1R antibody cabiralizumab with BMS' Opdivo (nivolumab).
-
Proceeds will be used to complete the ongoing pivotal TRCA-301 Phase 3 clinical trial of TRC101.
-
Exonics Therapeutics closed on a $40M Series A financing which was led by The Column Group.
-
Fresh off the heels of a $201M liver disease R&D deal with Dicerna, Boehringer Ingelheim has struck another deal targeting liver disease with MiNA Therapeutics.
-
Kerrisdale believes that Prothena's lead drug NEOD001 will fail in its current Phase 2b and Phase 3 trials.
-
The updated data will be presented at the 2017 Society for Immunotherapy of Cancer Annual Meeting.
-
OncoSec Medical today announced the appointment of Daniel J. O'Connor as CEO of the Company.
-
The Q3 earnings season is approaching its end with 81.2% of the S&P 500 companies having already released results.
-
The hearing will focus on the therapeutic potential and ethical issues of using CRISPR technology to alter human DNA.
-
Fortress Biotech Announces Cellvation’s CEVA101 Granted FDA Regenerative Medicine Advanced Therapy Designation for the Treatment of Traumatic Brain Injury
11/8/2017
CEVA101 is being developed in partnership with The University of Texas Health Science Center at Houston.
-
Immunovaccine Announces Regulatory Clearance for Phase II Clinical Trial Evaluating DPX-Survivac in Combination With Merck’s Checkpoint Inhibitor Pembrolizumab in DLBCL
11/8/2017
This trial is designed to evaluate the safety and efficacy of Immunovaccine’s lead candidate along with Merck’s pembrolizumab and low-dose cyclophosphamide in this patient population.
-
Astellas and Seattle Genetics Initiate Phase Ib Trial of Enfortumab Vedotin in Combination With Immune Checkpoint Inhibitor Therapies in Locally Advanced or Metastatic Urothelial Cancer
11/8/2017
Enfortumab vedotin is an investigational ADC designed to deliver the cell-killing agent MMAE to the target Nectin-4.
-
Nightstar Expands Pipeline With Novel Gene Therapy for the Treatment of Stargardt Disease
11/8/2017
Stargardt disease is the most common form of inherited juvenile macular dystrophy with a prevalence of one in 10,000.
-
Verseon’s Novel Anticancer Agents for Multidrug Resistant Tumors Presented at BIO-Europe 2017
11/8/2017
The data suggest that these drug candidates may be especially well-suited for the treatment of solid tumors resistant to existing chemotherapy agents.
-
Ignyta Announces New Data Highlighting Immune Modulation of RXDX-106 at the Society for Immunotherapy of Cancer (SITC) Meeting
11/8/2017
Ignyta today announced new preclinical data for RXDX-106 - a novel immunomodulatory agent that demonstrated potent anti-tumor activity, alone and in combination with checkpoint inhibitors, by modulating the tumor microenvironment (TME) through TYRO3, AXL, and MER (TAM) receptor tyrosine kinase (RTK) inhibition.
-
PDL BioPharma's Proposal to Acquire Neos Therapeutics Expires Today; PDL Urges Neos to Provide Update on Sale Process
11/8/2017
[08-November-2017] INCLINE VILLAGE, Nev., Nov. 8, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (NASDAQ: PDLI) reiterated that its proposal to acquire Neos Therapeutics, Inc. (NASDAQ: NEOS) for $10.25 per share in cash will expire today at market close. PDL originally made public its proposal to acquire Neos on October 26, 2017 at a premium of approximately 40 percent to the pre-proposal closin
-
VALNEVA Signs $39.6M IXIARO Supply Contract With U.S. Government
11/8/2017
The new agreement will supplement the initial contract Valneva signed with the US military in March 2016 as the maximum quantity of doses allowed in the precedent contract was reached earlier than expected.
-
Skyline Medical Announces Two Proposed Joint Ventures and New Strategic Focus on CRO Services
11/8/2017
New collaborations with Helomics and CytoBioscience to diversify Skyline's operations into the rapidly growing CRO Services sector.